OBJECTIVES To estimate predicted 3-year total CVE rates (per 1000) in Hispanic patients with mixed dyslipidemia treated with fenofibric acid and a statin compared to statin monotherapy. METHODS A disease outcomes model was used to predict 3-year total CVE rates (per 1000) using baseline lipid, and lipid efficacy, data of Hispanic patients with mixed dyslipidemia from a pooled analysis of three large, double-blind, Phase III, randomized controlled trials that evaluated the efficacy and safety of fenofibric acid 135mg combined with low-dose statin (LDS) (simvastatin 20 mg, rosuvastatin 10mg, atorvastatin 20mg) or moderate-dose statin (MDS) (simvastatin 40mg, rosuvastatin 20mg, atorvastatin 40mg) compared to equivalent dose statin monotherapy. Risk for primary and secondary CVE including myocardial infarction (MI), angina pectoris, and stroke were based on published risk equations from the Framingham Heart Study. Additional risk attributable to elevated TG levels is estimated using hazard ratios from the Copenhagen Heart Study. RESULTS Co-administration of fenofibric acid and LDS or MDS was predicted to reduce 3-year total CVE rates by 37% (from 33 to 21 per 1000) and 22% (from 31 to 24 per 1000) compared to LDS and MDS monotherapy, respectively. The majority of CVE were attributable to MI, followed by angina and stroke in all treatment groups. CONCLUSIONS These data suggest that the co-administration of fenofibric acid and LDS or MDS may result in a 37% and 22% reduction in 3-year total CVE rates in Hispanic patients with mixed dyslipidemia.